Skip to main content
. 2019 Apr 18;9(5):935–946. doi: 10.1002/2211-5463.12636

Figure 5.

Figure 5

Silencing of PTPRK reduces oxaliplatin sensitivity of CD133‐expressing colon cancer cells. (A) WST cell survival assay. SW480 derivatives were treated with indicated concentrations of oxaliplatin for 48 h and their viability was measured by WST assay. Data represent mean ± SD (n = 5) and asterisks indicate statistical significance of difference (P < 0.05, one‐way ANOVA). (B) Trypan blue dye‐exclusion assay. The indicated cells were exposed to 20 μm of oxaliplatin (blue bars) or left untreated (open bars). Forty‐eight hours after treatment, floating and attached cells were harvested and processed for trypan blue assay. Data represent mean ± SD (n = 3) and asterisks indicate statistical significance of difference (P < 0.05, one‐way ANOVA). (C) Western blot analysis. The indicated cells were exposed to 20 μm of oxaliplatin or left untreated. Forty‐eight hours after treatment, cell lysates (30 μg) were prepared from floating and attached cells and analyzed by immunoblot with the indicated antibodies. Actin was used as a loading control.